

Hormone replacement therapy : molecules and dosage

Estrogens

Molecule	Name	Presentation
ESTRADIOL 17 β	Oestrogel [®]	<i>Percutaneous gel/1 measure = 1.25 mg E2</i> <i>Adhesive transdermal system</i>
	Estraderm TTS [®]	25-50-100 μ g
	System [®]	50 μ g
	Oesclim [®]	25-50-100 μ g
	Menorest [®]	37.5-50-75-100 μ g
	Demestril [®]	<i>Micronized E2 per os</i>
ESTRADIOL VALERATE	Estrofem [®]	Tablets = 2 mg E2
	Oromone [®]	
	Provames [®]	
EQUINE CONJUGATED ESTROGENS	Progynova [®]	Tablets = 2 mg E2
ESTRIOL	Premarin [®]	Coated tablets
	Synapause [®]	Tablets = 2 mg
	Ovestin [®]	Tablets = 2.5 mg

Progestogens

Class	Pharmaceutical name	Dose per tablet (mg)	Usual daily dose (mg) \times 12-14 days
NORSTEROIDS	Not very used in France in this indication		
Estranes			
Norethisterone	Norluten [®]	10	
Norethisterone acetate	Primolut Nor [®]	10	2.5-10
Ethinodiol diacetate	Lutometrodiol [®]	2	2-8
Lynestrenol	Orgametril [®]	5	5-10
Gonanes	Norgestrel, desogestrel, gestoden, norgestimat : available only in association with ethinyl estradiol for contraception		
PREGNANES			
Medroxyprogesterone acetate	Farluta [®] , Prodasone [®]	10	10
Chlormadinone acetate	Luteran [®]	2-5	10
Medrogestone	Colprone 5 [®]	5	10
Cyproterone acetate	Androcur [®]	50	Not very used in this indication
NORPREGNANES			
Demegestone	Lutionex [®]	5	10
Promegestone	Surgestone [®]	0.25-0.5	0.5
Nomegestrol acetate	Lutenyl [®]	5	5
NATURAL PROGESTERONE and derivatives			
Micronized progesterone	Utrogestan [®]	100	200-300
Dydrogesterone or Retroprogesterone	Duphaston [®]	5-10	20

Estroprogestative treatments

Name	Composition
Divina®	Estradiol valerate 2 mg + medroxyprogesterone acetate 10 mg
Climene®	Estradiol valerate 2 mg + cyproterone acetate 1 mg
Kliogest®	Estradiol 2 mg + norethisterone acetate 1 mg (continuous)
Trisequens®	Estradiol 2 mg – 12 days/2 mg-10 days/1 mg-6 days + norethisterone acetate 1 mg-10 days

Abbreviations

Act	activity
Ag	antigen
Apo	apolipoprotein
AR	attributable risk
AT III	antithrombin III
bFGF	basic fibroblast growth factor
BMI	body mass index
BP	blood pressure
CAD	coronary artery disease
CAT	chloramphenicol acetyl transferase
CE	conjugated (equine) estrogens
CHD	coronary heart disease
cNOS	cellular NO synthase
co	cross-over
Cont	continous
CPA	cyproterone acetate (pregnane)
CVD(R)	cardiovascular disease (risk)
DB	double-blind
DBP	diastolic blood pressure
DD	didrogestone
DES	diethylstilbestrol
DEXA	dual-energy X-ray absorptiometry
DG	desogestrel (gonane)
E	estrogen(s)
E1	estrone
E2	estradiol-17 β (natural estrogen)
E2G	percutaneous gel estradiol-17 β
E2M	micronized estradiol-17 β
E2T	transdermal estradiol-17 β
E2V	estradiol valerate
EE	ethinyl estradiol 17 β
EGF	epidermal growth factor
EIA	enzyme immuno assay
EP (E(2)+P)	estrogenestrogen (opposed)
ER	estrogen receptor
ET-1	endothelin 1
F VII, VIII	factor VII, VIII
F ₁₊₂	1+2 prothrombin fragments
FCS	fetal calf serum
FPA	fibrinopeptide A
GFC	global fibrinolytic activity
HDL	high density lipoprotein (cholesterol)

HRT	hormone replacement therapy
HUVEC	human umbilical vein endothelial cells
ICC	immunocytochemistry
IHD	ischemic heart disease
LDL	low density lipoprotein (cholesterol)
LDL-R	low density lipoprotein receptor
LNG	levonorgestrel
Lp(a)	lipoprotein (a)
MA	megestrol acetate (norpregnane)
MED	medrogestrol (pregnane)
MI	myocardial infarction
MP	micronized progesterone
MPA	medroxyprogesterone acetate (pregnane)
MT	methyltestosterone
N	number of relevant women in the study
NA	norethisterone acetate (norpregnane)
NatMp	natural menopause
NETA	norethisterone acetate (norsteroid)
NG	norgestrel (gonane)
NIDDM	non insulin-dependent diabetes mellitus
NO(S)	nitrogen monoxide (synthase)
nr	not reported
ns	non statistically significant
OR	odds ratio
P	progesterone
PA	plasminogen activator
PAI	plasminogen activator inhibitor
PC	protein C
PDGF	platelet derived growth factor
PeriMp	perimenopausal
PG (F1, I2, F α)	prostaglandin
PI	pulsatility index
p.o.	<i>per os</i>
PostMp	postmenopausal
PR (F1, I2, F α)	progesterone receptor
PreMp	premenopausal
prosp	prospective
PS	protein S
R	randomized
Ren-2	renin-2
RI	resistance index
RIA	radio immuno assay
Rnase	ribonuclease
RR	relative risk
RT-PCR	reverse-transcriptase-polymerase chain reaction
SBP	systolic blood pressure
SD	sudden death
SMC	smooth muscle cell
SurMp	surgical menopause

TAT	thrombin-antithrombin
TBARS	thiobarbituric acid reactive substance
TC	total cholesterol
TG	triglycerides
TGF β	transforming growth factor β
TTS	transdermal therapeutic system
TX (B2)	thromboxane (B2)
VLDL	very low density lipoprotein (cholesterol)
VWF	von Willebrand factor
WB	western blot
WHR	waist-to-hip ratio
WT	wild type